Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 10/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 8/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23656992 | 1.00 | PSMB5 (0.52) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21365255 | 0.91 | PSMB5 (0.55) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29489248 | 0.88 | PSEN1 (0.53) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23628553 | 0.88 | PSEN1 (0.53) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13061974 | 0.87 | PSMB5 (0.54) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL932964 | 0.87 | PSMB5 (0.57) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3772142 | 0.83 | PSMB5 (0.56) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13061977 | 0.83 | PSMB5 (0.46) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3658623 | 0.83 | PSMB5 (0.46) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22388235 | 0.83 | PSMB5 (0.47) | PSMB5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| US-20210221791-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2021-07-22 | — | — | US | disclosed |
| EP-3497095-B1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | UNIV OSLO (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-10961223-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2021-03-30 | — | — | US | disclosed |
| US-20190284167-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649222-B2 | Compounds | SLC30A6, SLC39A11, SLC39A3 | PSMB5 811/4885PSEN1 1910/4885PSEN2 2783/4885 |
| US-10961223-B2 | Compounds | SLC30A6, SLC39A11, SLC30A5 | PSMB5 881/4885PSEN1 1941/4885PSEN2 2870/4885 |
| US-20190284167-A1 | COMPOUNDS | SLC30A6, SLC39A11, SLC30A5 | PSMB5 881/4885PSEN1 1941/4885PSEN2 2870/4885 |
| US-20210221791-A1 | COMPOUNDS | SLC30A6, SLC30A5, SLC39A11 | PSMB5 522/4885PSEN1 2138/4885PSEN2 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.